Tim  Cruickshank net worth and biography

Tim Cruickshank Biography and Net Worth

CFO of HeartBeam

Timothy Cruickshank, Chief Financial Officer (CFO), brings more than 15 years of experience with a proven track record of strategic planning, financial stewardship and commercial success. Most recently, he served as the CFO of ImpediMed, the world leader in the design and manufacture of medical devices and software services employing its pioneered bioimpedance spectroscopy (BIS) technology, for multiple indications including heart failure, protein calorie malnutrition, and lymphedema within oncology. During Mr. Cruickshank’s time at ImpediMed, he spearheaded the evolution of the company from a traditional medical device company to a medical technology company with a high margin Software-as-a-Service (SaaS) business model, through the launch of the SOZO® Digital Health Platform. He is also on the Executive Board of Directors for Big Brothers Big Sisters of San Diego County. Mr. Cruickshank received a Master of Business Administration from Keller Graduate School of Management and a Bachelor of Science in Accounting from Syracuse University.

What is Tim Cruickshank's net worth?

The estimated net worth of Tim Cruickshank is at least $26.57 thousand as of April 16th, 2026. Mr. Cruickshank owns 72,230 shares of HeartBeam stock worth more than $26,573 as of September 30th. This net worth estimate does not reflect any other investments that Mr. Cruickshank may own. Learn More about Tim Cruickshank's net worth.

How do I contact Tim Cruickshank?

The corporate mailing address for Mr. Cruickshank and other HeartBeam executives is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. HeartBeam can also be reached via phone at 610-729-7000 and via email at [email protected]. Learn More on Tim Cruickshank's contact information.

Has Tim Cruickshank been buying or selling shares of HeartBeam?

Tim Cruickshank has not been actively trading shares of HeartBeam within the last three months. Most recently, on Thursday, April 16th, Tim Cruickshank bought 31,250 shares of HeartBeam stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $25,000.00. Following the completion of the transaction, the chief financial officer now directly owns 72,230 shares of the company's stock, valued at $57,784. Learn More on Tim Cruickshank's trading history.

Who are HeartBeam's active insiders?

HeartBeam's insider roster includes Tim Cruickshank (CFO), Richard Ferrari (Director), Michael Jaff (Director), Marga Ortigas-Wedekind (Director), and Branislav Vajdic (President, Director). Learn More on HeartBeam's active insiders.

Are insiders buying or selling shares of HeartBeam?

In the last year, HeartBeam insiders bought shares 7 times. They purchased a total of 1,118,750 shares worth more than $895,000.00. In the last year, insiders at the medical research company sold shares 3 times. They sold a total of 307,146 shares worth more than $1,077,090.03. The most recent insider tranaction occured on April, 16th when CFO Tim Cruickshank bought 31,250 shares worth more than $25,000.00. Insiders at HeartBeam own 18.0% of the company. Learn More about insider trades at HeartBeam.

Information on this page was last updated on 4/16/2026.

Tim Cruickshank Insider Trading History at HeartBeam

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2026Buy31,250$0.80$25,000.0072,230View SEC Filing Icon  
2/14/2025Buy17,647$1.70$29,999.9017,647View SEC Filing Icon  
See Full Table

Tim Cruickshank Buying and Selling Activity at HeartBeam

This chart shows Tim Cruickshank's buying and selling at HeartBeam by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HeartBeam Company Overview

HeartBeam logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.38

50 Day Range

MA: $0.47
Low: $0.36
High: $0.59

2 Week Range

Now: $0.37
Low: $0.36
High: $4.00

Volume

4,039 shs

Average Volume

973,169 shs

Market Capitalization

$20.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A